Ser372
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser372  -  CP110 (human)

Site Information
PsPEPsMsPKMHRRR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 9318022

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 19 ) , immunoprecipitation ( 19 ) , mass spectrometry ( 2 , 3 , 4 , 5 , 6 , 8 , 9 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , mutation of modification site ( 19 ) , phosphopeptide mapping ( 19 )
Disease tissue studied:
brain cancer ( 18 ) , glioblastoma ( 18 ) , glioma ( 18 ) , breast cancer ( 4 ) , leukemia ( 11 ) , acute myelogenous leukemia ( 11 ) , lung cancer ( 5 , 9 ) , non-small cell lung cancer ( 9 ) , non-small cell lung adenocarcinoma ( 5 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 14 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 13 ) , H2077 (pulmonary) ( 9 ) , H322 (pulmonary) ( 9 ) , H322M (pulmonary) ( 9 ) , HCC366 (pulmonary) ( 9 ) , HCC78 (pulmonary) ( 9 ) , HeLa (cervical) ( 3 , 8 ) , HeLa S3 (cervical) ( 12 ) , HMLER ('stem, breast cancer') ( 4 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 4 ) , HOP62 (pulmonary) ( 9 ) , Jurkat (T lymphocyte) ( 6 , 15 , 16 , 17 ) , K562 (erythroid) ( 8 ) , KG-1 (myeloid) ( 11 ) , LOU-NH91 (squamous) ( 9 ) , lung ( 5 ) , M059K (glial) ( 18 ) , NCI-H1395 (pulmonary) ( 9 ) , NCI-H1568 (pulmonary) ( 9 ) , NCI-H157 (pulmonary) ( 9 ) , NCI-H1666 (pulmonary) ( 9 ) , NCI-H2030 (pulmonary) ( 9 ) , NCI-H460 (pulmonary) ( 9 ) , NCI-H520 (squamous) ( 9 ) , NCI-H647 (pulmonary) ( 9 ) , PC9 (pulmonary) ( 9 ) , WM239A (epidermal) ( 2 )

Upstream Regulation
Putative in vivo kinases:
CDK2 (human) ( 19 )
Kinases, in vitro:
CDK2 (human) ( 19 )

Downstream Regulation
Effects of modification on CP110:
intracellular localization ( 19 )
Effects of modification on biological processes:
cell cycle regulation ( 19 )

References 

1

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

4

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

5

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

6

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

7

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

8

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

9

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

10

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

11

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

12

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

13

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

14

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

15

Possemato A (2009) CST Curation Set: 6371; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

16

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

17

Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

18

Stokes M (2007) CST Curation Set: 2262; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

19

Chen Z, et al. (2002) CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell 3, 339-50
12361598   Curated Info